Mind Medicine (mindmed) INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Definium Therapeutics reported increased operating expenses and a wider net loss in Q1 2026, driven by significant investment in its DT120 and DT402 clinical programs, while advancing key trials.
Mind Medicine (MindMed) Inc. reported a significant increase in net loss and R&D expenses for Q3 2025, but bolstered its financial position with a $242.8 million capital raise post-quarter, extending its cash runway into 2028.
Mind Medicine (MindMed) Inc. reported increased net losses and cash burn in Q2 2025 as it significantly ramps up Phase 3 clinical trials for its lead product candidates, MM120 and MM402, while securing new debt financing.
MindMed's Q1 2025 results show increased R&D spending and a net loss, but the company is progressing with its clinical trials and has secured additional financing.
MindMed's Q3 2024 report highlights progress in clinical trials for MM120 and MM402, along with a strong cash position following recent financings.
MindMed's second quarter 2024 results show a net loss of $5.9 million, but the company has secured significant funding and is advancing its clinical programs.
MindMed's Q1 2024 results show a net loss of $54.4 million, but the company also highlights positive clinical trial data for MM120 and a significant capital raise of $163.6 million.